A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case

[1]  Mathias Dunkel,et al.  SuperPred: update on drug classification and target prediction , 2014, Nucleic Acids Res..

[2]  W. Fleischhacker,et al.  Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia , 2014, International clinical psychopharmacology.

[3]  S. Moritz,et al.  Effects of dopaminergic modulation on automatic semantic priming: a double-blind study. , 2014, Journal of psychiatry & neuroscience : JPN.

[4]  N. Gençer,et al.  Antipsychotic agents screened as human carbonic anhydrase I and II inhibitors , 2014, Archives of physiology and biochemistry.

[5]  Damian Szklarczyk,et al.  STITCH 4: integration of protein–chemical interactions with user data , 2013, Nucleic Acids Res..

[6]  María Martín,et al.  Activities at the Universal Protein Resource (UniProt) , 2013, Nucleic Acids Res..

[7]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[8]  Yanli Wang,et al.  PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..

[9]  A. Butte,et al.  A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.

[10]  Abdelaziz Ghanemi.  Schizophrenia and Parkinson’s disease: Selected therapeutic advances beyond the dopaminergic etiologies , 2013 .

[11]  Thomas C. Wiegers,et al.  A CTD–Pfizer collaboration: manual curation of 88 000 scientific articles text mined for drug–disease and drug–phenotype interactions , 2013, Database J. Biol. Databases Curation.

[12]  Joshua F. McMichael,et al.  DGIdb - Mining the druggable genome , 2013, Nature Methods.

[13]  Zhongming Zhao,et al.  Characterization of Schizophrenia Adverse Drug Interactions through a Network Approach and Drug Classification , 2013, BioMed research international.

[14]  Tudor I. Oprea,et al.  The CARLSBAD Database: A Confederated Database of Chemical Bioactivities , 2013, Database J. Biol. Databases Curation.

[15]  Nancy Légaré,et al.  Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. , 2013, Medical hypotheses.

[16]  P. Sanseau,et al.  Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.

[17]  Anushya Muruganujan,et al.  PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees , 2012, Nucleic Acids Res..

[18]  Wigard Me,et al.  [Addition of fluvoxamine to clozapine: theory and practice]. , 2013 .

[19]  A. V. Van Gool,et al.  [Addition of fluvoxamine to clozapine: theory and practice]. , 2013, Tijdschrift voor psychiatrie.

[20]  C. Fuchs,et al.  Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine–betahistine combination , 2012, Psychopharmacology.

[21]  N. Kanahara,et al.  A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia: A Preliminary Study , 2012, Journal of clinical psychopharmacology.

[22]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[23]  P. Bork,et al.  Drug discovery in the age of systems biology: the rise of computational approaches for data integration. , 2012, Current opinion in biotechnology.

[24]  Hua Xu,et al.  DTome: a web-based tool for drug-target interactome construction , 2012, BMC Bioinformatics.

[25]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[26]  Jianmin Wu,et al.  PINA v2.0: mining interactome modules , 2011, Nucleic Acids Res..

[27]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[28]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[29]  Pankaj Agarwal,et al.  Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.

[30]  Xiaohua Douglas Zhang.  Optimal High-Throughput Screening: Practical Experimental Design and Data Analysis for Genome-Scale RNAi Research , 2011 .

[31]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[32]  Xiaohua Douglas Zhang.  Optimal High-Throughput Screening: Optimal High-Throughput Screening , 2011 .

[33]  A. Meyer-Lindenberg,et al.  Polypharmacy in schizophrenia , 2010, Current opinion in psychiatry.

[34]  Michael Schroeder,et al.  SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions , 2009, Nucleic Acids Res..

[35]  陳俊興,et al.  Treatment Strategy for Refractory Schizophrenia: Drug Interaction between Clozapine and Fluvoxamine , 2010 .

[36]  R. Iyengar,et al.  Systems pharmacology. , 2010, The Mount Sinai journal of medicine, New York.

[37]  Peilin Jia,et al.  A multi-dimensional evidence-based candidate gene prioritization approach for complex diseases-schizophrenia as a case , 2009, Bioinform..

[38]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[39]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[40]  John P. Overington,et al.  Genomic-scale prioritization of drug targets: the TDR Targets database , 2008, Nature Reviews Drug Discovery.

[41]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[42]  Michael Darsow,et al.  ChEBI: a database and ontology for chemical entities of biological interest , 2007, Nucleic Acids Res..

[43]  Xiaomin Luo,et al.  PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.

[44]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[45]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[46]  Tatiana A. Tatusova,et al.  Entrez Gene: gene-centered information at NCBI , 2004, Nucleic Acids Res..

[47]  S. Runyon,et al.  Dopamine transporter ligands: recent developments and therapeutic potential. , 2006, Current topics in medicinal chemistry.

[48]  P. Masand,et al.  Polypharmacy in schizophrenia , 2006, International journal of psychiatry in clinical practice.

[49]  Oliver Freudenreich,et al.  Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. , 2005, The Journal of clinical psychiatry.

[50]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[51]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[52]  F. Dickerson,et al.  Comorbidity of Medical Illnesses Among Adults With Serious Mental Illness Who Are Receiving Community Psychiatric Services , 2004, The Journal of nervous and mental disease.

[53]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[54]  B. Roth,et al.  The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .

[55]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..